Prostate Cancer-Specific of DD3-driven oncolytic virus-harboring mK5 gene-Reference-Cited by-同舟云学术

Prostate Cancer-Specific of DD3-driven oncolytic virus-harboring mK5 gene

Published:2018-12-24 Issue:1 Volume:14 Page:1-9
ISSN:2391-5463
Container-title:Open Medicine
language:
Short-container-title:

Author:

Hao Jiali¹,Xie Wenjie¹,Li Hui²,Li Runsheng³

Affiliation:

1. Xinyuan Institute of Medicine and Biotechnology, Zhejiang SciTech University, Hangzhou310018, China

2. Shanghai Yuansong biotechnology Co., Ltd., Shanghai, China

3. Key Laboratory of Contraceptive Drugs and Devices of NPFPC, Shanghai Institute of Planned Parenthood Research, Shanghai, China

Abstract

AbstractProstate cancer (PCa) is the second most diagnosed cancer in Western male population. In this study, we insert mK5 (the mutational kringle5 of human plasminogen) into a DD3-promoted (differential display code 3) oncolytic adenovirus to construct OncoAd.mK5.DD3. E1A.dE1B, briefly, OAd.DD3.mK5. DD3 is one of the most prostate cancer specific promoters which can transcriptionally control adenoviral replication. mK5 has been proved to be able to inhibit the tumor angiogenesis and inhibit cell proliferation. Our results suggested that targeting PCa with OAd.DD3.mK5 elicited strong antitumor effect.

Publisher

Walter de Gruyter GmbH

Subject

General Medicine

Link

https://www.degruyter.com/document/doi/10.1515/med-2019-0001/pdf

Reference60 articles.

1. High-malignancy orthotopic nude mouse model of human prostate cancer lncap;Prostate,2015

2. Oncolytic adenovirus complexes coated with lipids and calcium phosphate for cancer gene therapy;Acs Nano,2016

3. Selective inhibition by kringle 5 of human plasminogen on endothelial cell migration, an important process in angiogenesis;Biochem Biophys Res Commun,1998

4. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance;Nature,1997

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A review exploring the fusion of oncolytic viruses and cancer immunotherapy: An innovative strategy in the realm of cancer treatment;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-07

2. Hypoxia effects on oncolytic virotherapy in Cancer: Friend or Foe?;International Immunopharmacology;2023-09

3. Oncolytic viral therapy: a review and promising future directions;Journal of Neurosurgery;2023-08-01

4. Current status and progress of the development of prostate cancer vaccines;Journal of Cancer;2023

5. Combined oncolytic adenovirus carrying MnSOD and mK5 genes both regulated by survivin promoter has a synergistic inhibitory effect on gastric cancer;Neoplasma;2022